|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1992-6-10
|
|
pubmed:abstractText |
Hepatoprotective effects of KF-14363 were investigated in the following experimental models. KF-14363 inhibited the increase in serum glutamate pyruvate transaminase (GPT) dose-dependently, and a significant inhibition was noted at a dose of 30 mg/kg or more. KF-14363 significantly inhibited the D-galactosamine (D-gal)-induced increase in serum transaminase by oral administration at 250 mg/kg x 1 and 250 mg/kg x 2 doses. The D-gal-induced decrease in total protein levels was inhibited at doses of 100 mg/kg x 2 and 250 mg/kg x 2. KF-14363 (100 mg/kg or more) significantly inhibited the increase in liver triglyceride levels induced by DL-ethionine (250 mg/kg x 3). KF-14363 (300 mg/kg) significantly inhibited the D-gal plus lipopolysaccharide-induced increase in GPT. At 100 mg/kg or less, however, an inhibiting tendency was noted, which was not significant as the values varied widely. KF-14363 (100 mg/kg) significantly inhibited Propionibacterium acnes plus lipopolysaccharide-induced mortality at 7 and 8 hr, and it showed an inhibitory tendency at 24 hr. These results demonstrate that KF-14363 is a compound that has a protective effect against the damage induced in various experimental liver injury models with different mechanisms.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0021-5198
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
127-36
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:1812294-Alanine Transaminase,
pubmed-meshheading:1812294-Animals,
pubmed-meshheading:1812294-Aspartate Aminotransferases,
pubmed-meshheading:1812294-Benzazepines,
pubmed-meshheading:1812294-Carbon Tetrachloride,
pubmed-meshheading:1812294-Disease Models, Animal,
pubmed-meshheading:1812294-Drug-Induced Liver Injury,
pubmed-meshheading:1812294-Ethionine,
pubmed-meshheading:1812294-Galactosamine,
pubmed-meshheading:1812294-Lipopolysaccharides,
pubmed-meshheading:1812294-Liver,
pubmed-meshheading:1812294-Male,
pubmed-meshheading:1812294-Mice,
pubmed-meshheading:1812294-Mice, Inbred BALB C,
pubmed-meshheading:1812294-Propionibacterium acnes,
pubmed-meshheading:1812294-Rats,
pubmed-meshheading:1812294-Rats, Inbred Strains,
pubmed-meshheading:1812294-Thiazoles,
pubmed-meshheading:1812294-Triglycerides
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
Hepatoprotective effects of 1-[(2-thiazolin-2-yl)-amino]acetyl-4-(1,3-dithiol-2-ylidene)-2,3,4,5- tetrahydro-1H-1-benzazepin-3,5-dione hydrochloride (KF-14363) in various experimental liver injuries.
|
|
pubmed:affiliation |
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Japan.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
